|
| 37259556 | Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. | Haematologica | 2024 |
| 36634298 | Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib. | JCO Precis Oncol | 2023 |
| 37517413 | Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. | Lancet Haematol | 2023 |
| 37611729 | Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice. | Exp Hematol | 2023 |
| 37021939 | Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. | Cancer Med | 2023 |
| 37042865 | Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. | Blood Adv | 2023 |
| 37203407 | Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. | Am J Hematol | 2023 |
| 37034738 | Interpretable spatial cell learning enhances the characterization of patient tissue microenvironments with highly multiplexed imaging data. | bioRxiv | 2023 |
| 36581736 | DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. | Nat Cancer | 2023 |
| 34551507 | Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. | Haematologica | 2022 |
| 35499819 | Defining disease modification in myelofibrosis in the era of targeted therapy. | Cancer | 2022 |
| 35367529 | Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromes. | Exp Hematol | 2022 |
| 36969740 | Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. | Cancer Res Commun | 2022 |
| 36467816 | Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. | EJHaem | 2022 |
| 36075392 | Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35869266 | Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. | Leukemia | 2022 |
| 35995947 | Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. | Nat Genet | 2022 |
| 35255234 | Momelotinib reduces transfusion requirements in patients with myelofibrosis. | Leuk Lymphoma | 2022 |
| 35128632 | Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. | Br J Haematol | 2022 |
| 34644371 | Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition. | Blood Adv | 2022 |
| 33423550 | MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. | Future Oncol | 2021 |
| 34873345 | Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. | Nat Med | 2021 |
| 33963182 | Co-evolution of tumor and immune cells during progression of multiple myeloma. | Nat Commun | 2021 |
| 34036230 | Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. | JCO Precis Oncol | 2021 |
| 34140953 | Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms. | Front Immunol | 2021 |
| 34193440 | A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. | Cancer Discov | 2021 |
| 33400685 | Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. | JCI Insight | 2021 |
| 32127404 | Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time. | Cancer Discov | 2020 |
| 31880950 | Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | J Clin Oncol | 2020 |
| 32063527 | Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. | Clin Lymphoma Myeloma Leuk | 2020 |
| 33232476 | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. | Blood Adv | 2020 |
| 32915978 | ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. | Blood Adv | 2020 |
| 32886902 | Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 30635625 | Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera. | Leukemia | 2019 |
| 31366621 | Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. | Blood | 2019 |
| 30718771 | Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. | Leukemia | 2019 |
| 30426661 | Identification of functionally primitive and immunophenotypically distinct subpopulations in secondary acute myeloid leukemia by mass cytometry. | Cytometry B Clin Cytom | 2019 |
| 29119847 | Myeloid/lymphoid neoplasms with FGFR1 rearrangement. | Leuk Lymphoma | 2018 |
| 30148454 | Neutralize the neutrophils! Neutrophil β1/β2 integrin activation contributes to JAK2-V617F-driven thrombosis. | J Clin Invest | 2018 |
| 30122202 | Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. | Clin Lymphoma Myeloma Leuk | 2018 |
| 30089725 | Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. | JCI Insight | 2018 |
| 30245100 | Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. | Clin Lymphoma Myeloma Leuk | 2018 |
| 30423295 | JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. | Cancer Cell | 2018 |
| 30348809 | A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. | Cancer Res | 2018 |
| 30545997 | Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 30343900 | High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. | Cell | 2018 |
| 30445041 | High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. | Cell | 2018 |
| 29048104 | Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. | Br J Haematol | 2018 |
| 28008177 | Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. | Leukemia | 2017 |
| 28220932 | A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. | Br J Haematol | 2017 |